Certificate of

Advanced Studies in
Personalized Molecular
Oncology

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 1/17

Certificate of Advanced Studies (CAS) in
Personalized Molecular Oncology

Overview technical, regulatory and ethical challenges. Target audience

Cutting-edge technologies, like next-gen- As an important outcome, it will establish a The CAS targets a mu
eration-sequencing (NGS), combined with common language between the wide range ence of professionals in
the development of targeted therapies of professionals involved in the personal- ized molecular oncolog
are now revolutionizing clinical practice, ized oncology process, from biologists, bio- tory managers, biologist
thereby bringing new complexity to the field informaticians, pathologists to clinicians, pathologists, geneticists
of oncology. The Certificate of Advanced enabling an efficient and better informed maceutical company em
Studies (CAS) in Personalized Molecular use of e.g. genomic data for both routine will be selected on the b
Oncology aims at providing a comprehen- clinical practice and clinical research. More- demonstrated interest
sive and integrative view of the field, by over, it should empower professionals to personalized oncology,
covering all the aspects involved along the develop a vision in their own institution, by hold a university degre
pipeline: (i) tumor biology and genetics, critically evaluating the potential benefits

Detailed module program

(ii) molecular pathology, (iii) clinical bioin-
formatics, and (iv) clinical oncology.
and limitations of current and future devel-
opments in personalized oncology.
Needs
Medical practice is und
Edition 4: 2022-2023
First of its kind in Switzerland, it will focus
on the methodologies used to generate,
The CAS is organized jointly by the Univer-
sity Hospital of Basel, the University Hospi-
around personalized m
the development of hig
analyze and interpret patients’ molecular tal of Lausanne, and the SIB Swiss Institute nologies. These techno
Document
profiles, alsoversion 1 –upon
touching 14 February 2022
the associated of Bioinformatics. quantities of data, pro
dented level of molecu
also raising new chall
and clinical laboratory
CAS Personalized Molecular Oncology | 10 ECTS | Duration: approx. 10 months
In oncology and hemato
Module title Module coordination profiles are now incre
notably for clinicians to
Module 1 Tumor biology and genetics CHUV Cancer Genetic drug for the right pat
generate, analyze and
Module 2 Molecular pathology USB Pathology data is however comp
a plurality of skills. T
Module 3 Clinical bioinformatics SIB Clinical Bioinformatics need for continuing ed
idly evolving field, to en
Module 4 Clinical oncology USB Oncology als with various backgro
cate and collaborate effi
Mini-thesis Planned in small groups Program Board the personalized oncol
benefit of patient care.

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 2/17

 Module 1
Tumor biology & genetics

Dates
• 4, 5; 25, 26 November 2022 (28h presential teaching).

Location
• Lausanne, CHUV University Hospital.

Main topics
• Basic cytogenetics and molecular genetics
• Hereditary vs. acquired genetics
• Genetic recombination, DNA damage and repair
• Solid tumors and hematological malignancies
• Genetic predisposition to cancer
• Diagnostic genetic testing
• Tumor cell proliferation
• Clonal evolution & tumor heterogeneity

Learning objectives for participants

• Describe the mechanisms yielding to genetic variation, and be familiar with
the various types of genetic variants.
• Distinguish hereditary genetic anomalies from acquired genetic anomalies.
• Discuss the advantages and limitations of different genetic laboratory
methodologies for diagnostic testing.
• Demonstrate how to interpret non-hotspot mutations using public databases
and taking into account overall genomic aberrations and clonal evolution.
• Be aware of ethical implications of incidental genetic findings.

Prerequisites to attend the module

• Basic notions of biology.

Module coordinator
• Prof. Jacqueline Schoumans (CHUV)

Course format
• Lectures, exercises, group discussions and lab visit.

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 3/17

Day 1 – Introduction to hematological and hereditary cancers in adults and
molecular genetics
• [0h35] Welcome
o Introduction to the CAS (Dr Aitana Lebrand, SIB)
o Introduction to module 1 (Prof. Jacqueline Schoumans, CHUV)
§ All participants introduce themselves and their background
§ Brief introduction of clinical utility of somatic genetic testing with
overview of organization of laboratories performing genetic testing at
the CHUV

• [2h10] Introduction to molecular genetics (Dr Ilaria Scarpelli and Dr John

Walker, CHUV)
o Definition of genomics (whole genome, whole exome, panel),
transcriptomics, proteomics, metabolomics
o DNA structure: chromosomes, nucleotides, genes, introns, exons,
regulatory elements
o From DNA to proteins: transcription, translation, post-translational
modifications
o Roles of proteins in cells (regulatory/signaling networks), importance of
3D structure
o Genetic modifications
o Definitions of allele, genotype, haplotype, phenotype
o Types of mutations: SNVs, SNPs, insertions, deletions
o Effect of the mutations: synonymous, non-synonymous mutations;
nonsense, missense mutations; frameshifts
o Variant nomenclature

• [2h] Hereditary cancer in adults (Dr Benno Röthlisberger, Genetica AG,

Zurich)
o Hereditary breast cancer
o Genetic testing
o Genetic counseling
o Ethical aspects

• [1h20] Introduction to hematological neoplasia (Prof Caroline Arber,

CHUV)
o Introduction to hematopoiesis
o Classification of hematpoietic neoplasms (WHO)
o Overview of technologies needed for classification
o Overview of treatment options

• [1h20] Cellular therapies in hematologic malignancies (Prof Caroline Arber,

CHUV)
o Hematopoietic stem cell transplantation
o Chimeric antigen receptor T cell therapie

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 4/17

Day 2 – Introduction to childhood cancer and next generation sequencing data
analysis and interpretation

• [2h30] Hereditary cancer in children (Dr Raffaele Renella, CHUV)

o Predisposition to cancer by inherited genomic instability
o Example of Fanconi anemia and acute myeloid leukemia
o Patient demonstration

• [1h30] Next generation sequencing data analysis and interpretation

(Dr Ilaria Scarpelli and Dr John Walker, CHUV)
o Frequency of mutation in a tumor (VAF) and in population (MAF)
o Impact of the mutations: variant of uncertain significance, benign variant
vs. pathogenic prediction, variant databases
o Molecular risk stratification in hematological neoplasia

• [2h] Interactive workshop of genomic variant interpretation focusing on

hematological malignancies (practical exercises performed in small groups
using Seqpilot software package (laptops will be provided). (Dr Ilaria
Scarpelli and Dr John Walker, CHUV)

• [1h15] Continued interactive workshop & discussion of results of practical

exercises (Dr Ilaria Scarpelli and Dr John Walker, CHUV)

Day 3 – Cell biology and tumor genetics focusing on hematological

malignancies
• [0h45] Part 1 - Precision medicine in hematological malignancies
(Dr Sabine Blum, CHUV)
o History of first targeted therapy (precision medicine) in chronic myeloid
leukemia (CML)
o Development of Tyrosine kinase inhibitors (TKI)

• [0h40] Part 2 - Precision medicine in hematological malignancies

(Dr Sabine Blum, CHUV)
o Acquired resistant mutations
o Monitoring of treatment response by Minimal Residual Disease
measurements (MRD

• [0h30] Clonal evolution & Tumor heterogeneity in hematological neoplasia

(Dr Joop Jansen, Radboud University Medical Center Nijmegen)
RECORDED presentation and Q&A by email
o Clonal evolution in myeloid leukemia
o Clonal hematopoiesis of indeterminate potential (CHIP) mutations

• [0h30] Personalized approach, patient cases (Dr Sabine Blum, CHUV

• [2h] Usefulness of cytogenetics in hematological neoplasia (Prof Jacqueline

Schoumans CHUV)

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 5/17

 o Confirmation and WHO classification of disease
o Prognostication with scoring systems and risk stratification
o Treatment selection and response
o Interactive interpretive exercises with chromosome anomalies

• [2h30] Tumor genetics in the lab (Prof Jacqueline Schoumans, CHUV)

o Hereditary cancer genetics vs. acquired genetics
o Meiosis, mitosis, genetic mechanisms (e.g DNA repair, homologous
recombination, double hit chromothripsis)
o Solid tumor vs. hematology
o Brief overview of laboratory technologies and their capabilities and
limitations for detecting genetic aberrations in cancer such as insertions
o Introduction to group exercises genomic testing strategies in onco-
hematology

Day 4 – Diagnostic applications of tumor genetics focusing on hematological

malignancies
• [2h] Practical exercises concerning genetic testing strategies and
interpretation of results will be solved in small groups and discussed at the
end of the session in the entire group (Prof Jacqueline Schoumans,
CHUV)
• [1h] Practical exercises continued
• [3h] Practical demonstration of genetic methodologies and automation at
the oncogenomic hematology laboratory, CHUV
Demo organized
o Conventional karyotyping (Anne Rajakumar)
o FISH (Isabel Pinto)
o SNP-array (Jacqueline Schoumans)
o NGS gene panels and complementary molecular tests (Marion Rebeaud)
• [0h30] Summary and end of module in lunch room BH18 (Dr Aitana
Lebrand)

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 6/17

 Module 2
Molecular pathology

Dates
• 20, 21 January; 3, 4 February 2023 (28h presential teaching).

Location
• Basel, Basel University Hospital.

Main topics
• Sample classification and preparation
• Principles of nucleic acids extraction
• Sequencing platforms and setup
• Understanding gene panels
• Internal / external quality controls
• Laboratory accreditation
• Reporting clinically relevant genomic variants
• Interpreting a molecular profile

Learning objectives for participants

• Gain knowledge about the different types of specimens (e.g. tissue biopsy,
cytology, resections, blood samples).
• Get an overview about the currently used technological platforms in molecular
diagnostics (comparison with the research setting).
• Get familiar with all the steps that lead from sample collection to final
molecular report generation along with all possible bottlenecks.
• Algorithms for appropriate gene panel selection.
• Understand the basics (procedures and rules) of an accredited clinical
laboratory, including internal and external quality controls.
• Get familiar with the most common clinically relevant variants along with their
interpretation and classification system.

Prerequisites to attend the module

• Module 1 or equivalent knowledge.

Module coordinators
• PD Dr. Christian Ruiz (USB), Dr. Salvatore Piscuoglio (USB), PD Dr. Matthias
Matter (USB)

Course format
• Lectures, exercises, group discussions and lab visit.

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 7/17

Day 1 – General Introduction into Pathology and Molecular Pathology
• [0h30] Welcome and Introduction to the Institute of Pathology in Basel
(PD Dr. Christian Ruiz, USB, Prof. Dr. Luigi Terracciano, USB)

• [0h30] Different types of samples and requirements for molecular analysis

(PD Dr. Christian Ruiz, USB)

• [1h] Introduction into general pathology: general concepts of neoplasia

(PD Dr. Matthias Matter, USB)

• [1h] Overview of the techniques used in molecular pathology

(PD Dr. Matthias Matter, USB)

• [1h30] Lab visits:

o I: General pathology laboratory (45 min) (PD Dr. Christian Ruiz,
USB, Prof. Dr. Alexandar Tzankov, USB)
o II: Molecular pathology (45 min) (PD Dr. Michel Bihl, USB, Dr. Philip
Jermann, USB)

• [0h45] Different types of biomarkers: diagnostic, prognostic and predictive

(Prof. Dr. Luigi Terracciano, USB)

• [1h] Practical/Hands-on microscope: real-life cases of clinical pathology

(PD Dr. Matthias Matter, USB, Prof. Dr. Luigi Tornillo, GILAB AG)

• [0h45] Wrap up of the day, questions & answers

Day 2 – Intro into genomics; Tumor specific molecular pathology;

Accreditation; Molecular Pathology: Analysis of different tumor types
• [1h] Introduction into Genomics & NGS (Dr. Philip Jermann, USB)

• [1h] NGS panels for genomic analyses, BRCAness, TMB, genomic

biomarkers (Dr. Philip Jermann, USB)

• [0h45] Digital Pathology (Prof. Dr. Viktor Közer, University Hospital Zürich)

• [0h45] Molecular Pathology of Breast Cancer (PD Dr. Simone Münst, USB)

• [0h45] Laboratory Accreditation (Prof. Dr. Alexandar Tzankov, USB)

• [0h45] Molecular Pathology of the Lung Cancer (PD Dr. Spasenija Savic,
USB)

• [0h45] Molecular Pathology of Urogenital Cancers (PD Dr. Tatjana Vlajnic,

USB)

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 8/17

 • [0h45] Molecular Pathology of Gastrointestinal Tumors (PD Dr. Matthias
Matter, USB, Prof. Dr. Luigi Terracciano, University of Basel)

• [1h] QC in Molecular Pathology (Dr. Philip Jermann, USB)

Day 3 – New cutting-edge Technologies in Molecular Pathology

• [1h] Advances in liquid biopsies (CTCs) (Prof. Dr. Nicola Aceto, ETH
Zürich)

• [1h] Single cell sequencing (Dr. Guglielmo Roma, GSK, Italy; VIRTUAL)

• [1h] Organoids for diagnostics (Prof Dr. Marianna Kruithof-de-Julio, DBMR,

University of Berne)

• [14h15-15h00] Molecular Pathology of Soft Tissue and Bone Tumors (Prof.

Dr. Daniel Baumhoer)

• [1h] BRCAness, HRD etc. (Prof. Dr. Tom McKee, HUG)

• [0h45] Analysis of real-life diagnostics (Prof. Dr. Tom McKee, HUG)

• [1h] Guidelines for diagnostic reporting (PD Dr. Matthias Matter, USB)

Day 4 – Results, Data Interpretation, data usage, etc.

• [1h] How are variants classified? What is considered clinically significant?
(Dr. Philip Jermann, USB)

• [1h] Special Metabolomics (Prof. Dr. Theodor Alexandrov, EMBL,

Heidelberg; VIRTUAL)

• [1h] Computational Analysis (Dr. Charlotte Ng, DBMR University of Berne)

• [1h] Analysis of real-life cases using –omics technologies (Dr. Salvatore

Piscuoglio, USB)

• [1h] Cell-Free DNA (Prof. Dr. Davide Rossi, IOSI, Bellinzona)

• [0h45] Methylome Analysis (Dr. Jürgen Hench, USB)

• [0h45] Nanopore Sequencing (Dr. Jürgen Hench, USB)

• [1h] Data handling and IT regulations (Dr. Thierry Sengstag, University of

Basel, sciCORE)

• [0h45] Wrap up of the day, questions & answers

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 9/17

 Module 3
Clinical bioinformatics

Dates
• 17, 18 March; 31 March, 1 April 2023 (28h presential teaching).

Location
• Lausanne, University of Lausanne.

Main topics
• Data pre-processing
• Read mapping
• Variant calling
• Quality control
• Variant annotation
• Hardware, security, privacy
• Artificial intelligence (AI) basics
• AI current and future applications

Learning objectives for participants

• Communicate efficiently with bioinformaticians.
• Describe a bioinformatics analysis pipeline to call mutations from NGS data.
• Perform quality control at the run, read and variant levels.
• Use off-the-shelf bioinformatics tools to annotate and support the
interpretation of variants.
• Consider hardware, security and privacy issues when managing omics data.
• Understand how artificial intelligence contributes to and will further impact
personalized oncology.

Prerequisites to attend the module

• Modules 1 and 2, or equivalent knowledge.

Module coordinators
• Dr. Aitana Lebrand (SIB), Valérie Barbié (SIB)

Course format
• Lectures, hands-on, exercises and group discussions.

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 10/17

Day 1 – Somatic and germline variant calling
• [0h45] Introduction and general overview (Dr. Aitana Lebrand, SIB)

• [1h45] Pre-processing and quality control (Dr. Aitana Lebrand, SIB)

o HANDS-ON: Reads pre-processing.

• [1h] Sequence alignment and read mapping (Dr. Aitana Lebrand, SIB)

• [1h30] Bioinformatics for RNA-seq and CHIP-seq (Agnieszka Kraft, ETHZ)

• [1h30] HANDS-ON: Exploring BAM files (Dr. Yann Christinat, HUG/SIB;

Dr. Aitana Lebrand, SIB)

• [0h30] Sequencing depth, genome and gene coverage, variant frequency

(Dr. Aitana Lebrand, SIB)

• [1h] Variant calling (Dr. Edoardo Missiaglia, CHUV)

Day 2 – Variant quality control and annotation

I. QC at the variant-level
• [0h30] Example case (Dr. Yann Christinat, HUG/SIB).

• [1h15] HANDS-ON: Technical artifacts (Dr. Yann Christinat, HUG/SIB)

• [0h30] Copy number variants (CNVs) and other structural variants (SVs)
(Dr. Yann Christinat, HUG/SIB)

• [0h30] HANDS-ON on SVs in IGV (Dr. Yann Christinat, HUG/SIB)

II. Variant annotation

• [0h45] Effect and functional impact (Dr. Aitana Lebrand, SIB)

• [2h] HANDS-ON (Dr. Yann Christinat, HUG/SIB)

o Genes, transcripts and HGVS nomenclature.
o Spotting germline variants and assessing clonality.
o Annotation using bioinformatics tools.

• [0h30] DISCUSSION: Beyond gene panels (Dr. Yann Christinat, HUG/SIB;

Dr. Aitana Lebrand, SIB)

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 11/17

Day 3 – What next?
• [2h] Risks and probabilities for the interpretation of genetic results
(PD Dr. Frédéric Schütz, UNIL/SIB)

• [2h30] Molecular modeling: predicting the impact of variants on proteins

(Prof. Dr. Vincent Zoete, UNIL/CHUV/SIB)
o HANDS-ON: Impact of mutations on proteins 3D structure

• [1h30] Computational Cancer Pharmacogenomics (Dr. Michael Menden,

Helmholtz München)

• [1h30] Personalized cancer immunotherapy: predicting neo-epitopes

(Prof. Dr. David Gfeller, UNIL/CHUV/SIB)

Day 4 – Artificial intelligence: basics and applications

• [2h15] Introduction to image analysis (Dr. Andrew Janowczyk,

CHUV/UNIL/SIB)
o HANDS-ON: features extraction (manual and automated)

• [1h15] Machine learning basics (Dr. Aitana Lebrand, SIB)

• [1h15] HANDS-ON: predicting diagnosis from the extracted features

(Dr. Andrew Janowczyk, CHUV)

• [1h45] All you need is IT: a study case on all that’s hidden (Florent Tassy
and Valérie Barbié, SIB)

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 12/17

 Module 4
Clinical oncology

Dates
• 12, 13 May; 26, 27 May 2023 (28h presential teaching).

Location
• Basel, Basel University Hospital.

Main topics
• Tumor Physiology
• Tumor Immunology
• Cancer Statistics and Epidemiology
• Prognostic and Predictive Markers
• Targeted Therapies in Clinical Oncology
• Risks / probabilities for the interpretation of genetic results and counseling
• Clinical Trials in Molecular Oncology
• Molecular Tumor Board

Learning objectives for participants

• Describe main intracellular signaling pathways in solid tumors and molecular
aberrations hampering this signaling.
• Get detailed knowledge of immunological mechanisms and how these may be
used to optimize therapeutic approaches.
• Get a basic understanding of the principles underlying the design and
analysis of clinical trials in oncology.
• Understand the importance of predictive markers in molecular oncology.
• Get familiar with the most frequent molecular aberrations in solid tumors and
routinely used targeted therapies.
• Learn about genetic counseling and its implications for patients and families.

Prerequisites to attend the module

• Modules 1, 2, 3 or equivalent knowledge.

Module coordinators
• PD Dr. Dr. Sacha Rothschild (USB), PD Dr. Dr. Andreas Wicki (USZ)

Course format
• Lectures, exercises and group discussions.

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 13/17

Day 1 – Tumor Biology, Epidemiology and Basic Concepts of Cancer Therapy
• [1h] Welcome. Cancer statistics and epidemiology (PD Dr. Dr. Sacha
Rothschild, USB)

• [1h] Familiar cancer, cancer genetics (Prof. Karl Heinimann, USB)

• [2h] Basic concepts of cancer therapy: (PD Dr. Dr. Sacha Rothschild, USB)
o Surgery, radiation therapy, systemic therapy
o Adjuvant, neoadjuvant, palliative
o Markers for systemic therapy: prognostic, predictive
o Definitions: OS, PFS, ORR, etc.

• [2h] Tumor biology: from molecular biology of cancer to targets for anti-
cancer drugs (Dr. Nicola Miglino, KSBL)
o What are the hallmarks of cancer (Weinstein/Hanahan)?
o What hallmarks are druggable?
o Clinical data for drugs targeting hallmarks of cancer
o Clinical data for markers of benefit in targeted therapies
o Mechanisms of resistance to targeted therapies

• [1h] Questions & Answers, wrap-up of the day

Day 2 – Tumor Immunology, Genomic Reports, Response Prediction

• [2h] Tumor immunology: how to get an immune response against cancer
(PD Dr. Dr. Heinz Läubli, USB)
o What mechanisms prevent the immune system to attack cancer
cells?
o How can we overcome silencing of the immune system?
o What are druggable targets for immuno-oncology?
o Clinical data for drugs targeting the immune system
o Clinical data for markers of benefit in immune therapies

• [1h] Overview: what markers can predict outcome of therapies? (PD Dr.
Dr. Andreas Wicki, KSBL)
o Clinical parameters
o Radiology parameters
o Histology
o Immunohistochemistry
o FISH
o Comparative genomic hybridization
o Sequencing of DNA, RNA (genomics, transcriptomics)
o Others

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 14/17

 • [2h] Using genetic markers to predict therapy in cancer patients (PD Dr.
Dr. Andreas Wicki, KSBL)
o Bulk sequencing vs single cell sequencing
o Tissue vs liquid biopsy
o Targeted/amplicon-based sequencing vs whole exome/genome
o Issue of interpretation
o Service providers in Switzerland
o Clinically relevant turn-around time
o Integration of genetic data in clinical routine
o DISCUSSION: ethical issues with genetic data (germline vs tumor
DNA)

• [2h] How do you read a genomic report as a clinician? (PD Dr. Dr. Sacha
Rothschild, USB)
o Basics: sources of information, databases
o Tips and tricks
o HANDS-ON: interpret bulk DNA sequencing report

Day 3 – Clinical Oncology, Drug Development in Oncology

• [2h] Current clinical standard: Interpreting predictive markers (both
genomics and others) in the big four: part 1 (colorectal and urogenital)
(PD Dr. Arnoud Templeton, Claraspital Basel / PD Dr. Dr. Andreas Wicki,
KSBL)

• [2h] Current clinical standard: Interpreting predictive markers (both

genomics and others) in the big four: part 2 (breast and lung)
(PD Dr. Marcus Vetter, USB / PD Dr. Dr. Sacha Rothschild, USB)

• [1h30] Point of care: decisions at the molecular tumor board

(PD Dr. Dr. Sacha Rothschild, USB / PD Dr. Dr. Andreas Wicki, KSBL
o How can a molecular board improve care for cancer patients?
o HANDS ON: simulate molecular board

• [0h30] CAS mini-thesis: presentation of topics and general explanations

(Dr. Aitana Lebrand, SIB)

• [2h] Overview: drug development in oncology (PD Dr. Dr. Andreas Wicki,
KSBL)
o Preclinical
o Early phase
o Late phase and approval
o Post marketing studies
o Attrition rate
o Clinical trial protocol, role of ethical committees and Swissmedic,
informed consent
o Primary endpoints vs secondary endpoints vs exploratory endpoints

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 15/17

 o Relevance of endpoints in clinical trials: OS, PFS, TTP, ORR, etc.
o How to interpret a clinical trial
o HANDS-ON: detailed analysis of current clinical trial protocols

• [1h30] Questions & Answers, wrap-up of the day

Day 4 – Predictive Biomarkers in Clinical Trials, Molecular Tumor Board

• [1h] Reimbursement: how to get a drug after your test predicts utility (PD
Dr. Dr. Sacha Rothschild, USB)
o DISCUSSION: assurance of equal treatment for all patients
(“off-label” use)

• [2h] Beyond genetics in therapy prediction (PD Dr. Dr. Andreas Wicki,
KSBL)
o Proteomics
o Single cell phenotyping
o Machine-based learning

• [1h] Algorithm trials: how to transform data in a robust prediction (PD Dr.
Dr. Andreas Wicki, KSBL)

• [0h30] Questions & Answers, wrap-up of the day

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 16/17

Educating
Talents
since 1460.

University of Basel
Department of Biomedicine
Hebelstrasse 20
CH-4031 Basel

pmo.unibas.ch

SIB Swiss Institute of Bioinformatics

Clinical Bioinformatics
Ch. des Mines 9
CH-1202 Geneva

[email protected]

CAS-PMO – Detailed Program 2022-2023 – pmo.unibas.ch 17/17